MA39109B1 - Nouveau composé pour le traitement de l'hypoglycémie grave - Google Patents

Nouveau composé pour le traitement de l'hypoglycémie grave

Info

Publication number
MA39109B1
MA39109B1 MA39109A MA39109A MA39109B1 MA 39109 B1 MA39109 B1 MA 39109B1 MA 39109 A MA39109 A MA 39109A MA 39109 A MA39109 A MA 39109A MA 39109 B1 MA39109 B1 MA 39109B1
Authority
MA
Morocco
Prior art keywords
treatment
new compound
severe hypoglycemia
hypoglycemia
severe
Prior art date
Application number
MA39109A
Other languages
English (en)
Other versions
MA39109A1 (fr
Inventor
Jorge Alsina-Fernandez
Robert Chadwick Cummins
Lili Guo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39109A1 publication Critical patent/MA39109A1/fr
Publication of MA39109B1 publication Critical patent/MA39109B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Removal Of Specific Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne un nouveau composé utile dans le traitement de l'hypoglycémie.
MA39109A 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie grave MA39109B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917597P 2013-12-18 2013-12-18
PCT/US2014/069643 WO2015094875A1 (fr) 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie grave

Publications (2)

Publication Number Publication Date
MA39109A1 MA39109A1 (fr) 2017-09-29
MA39109B1 true MA39109B1 (fr) 2018-04-30

Family

ID=52278802

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39109A MA39109B1 (fr) 2013-12-18 2014-12-11 Nouveau composé pour le traitement de l'hypoglycémie grave

Country Status (27)

Country Link
US (1) US9695225B2 (fr)
EP (1) EP3083668A1 (fr)
JP (1) JP2017509584A (fr)
KR (1) KR20160075825A (fr)
CN (1) CN105814076A (fr)
AP (1) AP2016009242A0 (fr)
AR (1) AR098614A1 (fr)
AU (1) AU2014366424B2 (fr)
BR (1) BR112016012067A2 (fr)
CA (1) CA2928985A1 (fr)
CL (1) CL2016001472A1 (fr)
CR (1) CR20160226A (fr)
DO (1) DOP2016000096A (fr)
EA (1) EA201690914A1 (fr)
EC (1) ECSP16024798A (fr)
GT (1) GT201600117A (fr)
HK (1) HK1224304A1 (fr)
IL (1) IL245400A0 (fr)
MA (1) MA39109B1 (fr)
MX (1) MX2016007982A (fr)
NZ (1) NZ719463A (fr)
PE (1) PE20160848A1 (fr)
PH (1) PH12016501182A1 (fr)
SG (1) SG11201604154SA (fr)
TN (1) TN2016000181A1 (fr)
TW (1) TW201609127A (fr)
WO (1) WO2015094875A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (fr) 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
EP3921336B1 (fr) 2019-02-05 2023-03-01 Eli Lilly And Company Agonistes analogiques du glucagon et leurs procédés d'utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891105B1 (fr) 2005-06-13 2012-04-11 Imperial Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CN101578102B (zh) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
TWI541023B (zh) * 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
WO2010148089A1 (fr) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Composés de glucagon actifs sur le récepteur gip
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011075393A2 (fr) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon/glp-i
RU2012153753A (ru) * 2010-05-13 2014-06-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
HRP20181591T1 (hr) * 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
WO2013004983A1 (fr) * 2011-07-04 2013-01-10 Imperial Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
ES2602486T3 (es) * 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP

Also Published As

Publication number Publication date
SG11201604154SA (en) 2016-07-28
AU2014366424B2 (en) 2017-02-16
US20160311881A1 (en) 2016-10-27
MA39109A1 (fr) 2017-09-29
KR20160075825A (ko) 2016-06-29
EA201690914A1 (ru) 2016-09-30
BR112016012067A2 (pt) 2017-09-26
TW201609127A (zh) 2016-03-16
PE20160848A1 (es) 2016-09-10
DOP2016000096A (es) 2016-08-15
NZ719463A (en) 2017-09-29
ECSP16024798A (es) 2017-05-31
JP2017509584A (ja) 2017-04-06
CN105814076A (zh) 2016-07-27
EP3083668A1 (fr) 2016-10-26
US9695225B2 (en) 2017-07-04
AU2014366424A1 (en) 2016-05-19
CL2016001472A1 (es) 2017-03-10
CR20160226A (es) 2016-07-12
CA2928985A1 (fr) 2015-06-25
IL245400A0 (en) 2016-06-30
AR098614A1 (es) 2016-06-01
GT201600117A (es) 2017-07-06
PH12016501182A1 (en) 2016-07-25
WO2015094875A1 (fr) 2015-06-25
HK1224304A1 (zh) 2017-08-18
AP2016009242A0 (en) 2016-06-30
MX2016007982A (es) 2016-09-09
TN2016000181A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
MA37740A1 (fr) Seringue
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201491391A1 (ru) Терапевтически активные соединения и способы их применения
EA201500738A1 (ru) Способ получения замещенных оксиранов и триазолов
AR095097A1 (es) Compuestos de fenoxietoxi
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
CO7141429A2 (es) Nuevos compuestos de pirazol
EA201690763A1 (ru) Лечение рака поджелудочной железы
MA39110B1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA39109A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie grave
MA42166B1 (fr) Seringue
MA39108A1 (fr) Nouveau composé pour le traitement de l'hypoglycémie sévère
MA39019A1 (fr) Acétate de 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undéc-2-yl)but-1-én-1-yl]-2-méthylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-bêta-d-glucopyranoside
EA201690214A1 (ru) Способ лечения гипертрофической кардиомиопатии
MA39432B1 (fr) Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu'inhibiteur de bace
EA201690593A1 (ru) Новые соединения мочевины
UA113753C2 (xx) Фенілзаміщені кетоеноли для боротьби з паразитами риб
MA38931B1 (fr) Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
EA201600013A1 (ru) Основание ковша и ковш
MA38411B1 (fr) Inhibiteurs de cdc7